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Abstract Sirt3 is a mitochondrial NAD?-dependent
deacetylase that governs mitochondrial metabolism and
reactive oxygen species homeostasis. Sirt3 deficiency has
been reported to accelerate the development of the meta-
bolic syndrome. However, the role of Sirt3 in atheroscle-
rosis remains enigmatic. We aimed to investigate whether
Sirt3 deficiency affects atherosclerosis, plaque vulnerabil-
ity, and metabolic homeostasis. Low-density lipoprotein
receptor knockout (LDLR-/-) and LDLR/Sirt3 double-
knockout (Sirt3-/-LDLR-/-) mice were fed a high-cho-
lesterol diet (1.25 % w/w) for 12 weeks. Atherosclerosis
was assessed en face in thoraco-abdominal aortae and in
cross sections of aortic roots. Sirt3 deletion led to hepatic
mitochondrial protein hyperacetylation. Unexpectedly,
though plasma malondialdehyde levels were elevated in
Sirt3-deficient mice, Sirt3 deletion affected neither plaque
burden nor features of plaque vulnerability (i.e., fibrous cap
thickness and necrotic core diameter). Likewise, plaque
macrophage and T cell infiltration as well as endothelial
activation remained unaltered. Electron microscopy of
aortic walls revealed no difference in mitochondrial mic-
roarchitecture between both groups. Interestingly, loss of
Sirt3 was associated with accelerated weight gain and an
impaired capacity to cope with rapid changes in nutrient
supply as assessed by indirect calorimetry. Serum lipid
levels and glucose tolerance were unaffected by Sirt3
deletion in LDLR-/- mice. Sirt3 deficiency does not affect
atherosclerosis in LDLR-/- mice. However, Sirt3 controls
systemic levels of oxidative stress, limits expedited weight
gain, and allows rapid metabolic adaptation. Thus, Sirt3
may contribute to postponing cardiovascular risk factor
development.
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Abbreviations
HDAC Histone deacetylase
NAD? Nicotinamide adenine dinucleotide
NADPH Nicotinamide adenine dinucleotide
phosphate
ROS Reactive oxygen species
TCA cycle Tricarboxylic acid cycle
MnSOD Manganese superoxide dismutase
Cat Catalase
IDH2 Isocitrate dehydrogenase 2
ORO Oil red O
VCAM-1 Vascular adhesion molecule-1
LDLR Low-density lipoprotein receptor
MCP-1 Monocyte chemoattractant protein-1
IL-1b Interleukin 1 beta
TNFa Tumor necrosis factor alpha
MDA Malondialdehyde
Ad lib Ad libitum
WAT White adipose tissue
RER Respiratory exchange ratio
Introduction
Sirtuins are a family of class III histone deacetylases (HDACs)
that distinguish themselves from other HDAC classes by their
dependency on nicotinamide adenine dinucleotide (NAD?) as
a cofactor [16]. Sirtuin activity is thus tightly linked to cellular
energy levels, confining their activity to times of caloric
restriction, the only regimen known to extend life span [12],
and delay the onset of age-related diseases, including athero-
sclerosis and myocardial infarction [6, 21].
Among seven mammalian homologues Sirt3 is the only
sirtuin that has been associated with human longevity and
aging in health [3, 11, 30]. A distinct variability in the
evolutionary conserved domain of the Sirt3 gene increased
the genotype-specific survival function in a homogeneous
population in southern Italy [30]. Accordingly, the pre-
sence of an intronic enhancer of the Sirt3 gene was
observed to be associated with survival at old ages [3].
Finally, Sirt3 showed the highest degree of genetic varia-
tion among 24 candidate genes of aging in a population of
healthy seniors aged 85 years and above, who had never
been diagnosed with cancer, diabetes, cardiovascular,
pulmonary or Alzheimer disease [11].
Together with Sirt4 and Sirt5, Sirt3 is targeted to the
mitochondrial matrix, where—through deacetylation of a
variety of substrates—it orchestrates mitochondrial
oxidative metabolism and controls reactive oxygen species
(ROS) homeostasis [1, 14, 23, 40]. In diverse contexts Sirt3
has been reported to regulate the tricarboxylic acid cycle
and oxidative phosphorylation [1, 5, 8, 31, 33, 43]. An
inevitable byproduct of these catabolic reactions is the
generation of ROS. Intriguingly, Sirt3 also governs the
detoxification of cellular ROS by regulating antioxidant
enzymes [4, 29, 34, 36–38, 40]. In vitro and in vivo Sirt3-
mediated deacetylation and activation of manganese
superoxide dismutase (MnSOD) reduced cellular ROS
levels [4, 29, 38]. Moreover, recent reports provide evi-
dence for a Sirt3-dependent activation of the mitochondrial
matrix protein isocitrate dehydrogenase 2 (IDH2), a major
source of NADPH, which in turn is vital for the reduction
of glutathione, an important cellular antioxidant [33, 43].
Sirt3-mediated activation of Foxo3a augmented the tran-
scription of both MnSOD and catalase (Cat), thereby pre-
venting mitochondrial ROS accumulation in
cardiomyocytes [36]. Along these lines, Sirt3 has been
reported to prevent detrimental oxidative-stress-related
phenotypes in a plethora of settings, including cardiac
hypertrophy, age-related hearing loss and ROS-induced
embryonic developmental arrest [18, 33, 36].
Excess ROS, subsequent mitochondrial DNA damage
and progressive respiratory chain dysfunction critically
contribute to the development of atherosclerosis [13, 25–
27]. Central risk factors of atherosclerosis such as hyper-
cholesterolemia and hyperglycemia lead to mitochondrial
dysfunction [20, 25]. Impaired mitochondrial integrity
along with accumulating cellular ROS underlie vascular
inflammation and promote atherogenesis from fatty streak
formation over lesion progress to plaque rupture [26, 41].
In a recent study, Sirt3 deficiency and the accompanying
mitochondrial protein hyperacetylation were reported to be
associated with the development of the metabolic syn-
drome, a cluster of hallmark risk factors for atherosclerosis,
including dyslipidemia, glucose intolerance, and central
obesity [2, 10, 15]. To date, the role of Sirt3 in vascular
biology and specifically in atherosclerosis remains
unknown.
Sirt3 orchestrates mitochondrial metabolism and gov-
erns cellular ROS homeostasis in a plethora of disease-
relevant settings. Thus, we hypothesized that Sirt3 provides
atheroprotection and maintains metabolic homeostasis. We
therefore investigated the role of Sirt3 in atherogenesis and
energy expenditure using a loss-of-function approach in a
mouse model of atherosclerosis.
Materials and methods
More detailed information is available in the supplemental
online material.
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Animals and diets
Mice were housed in cages with free access to chow and
water in a temperature-controlled facility with a 12-h light/
dark cycle. All experiments and animal care procedures
were approved by the local veterinary authorities and car-
ried out in accordance with our institutional guidelines.
Mice with a germline Sirt3 deletion were generated by
breeding mice with floxed Sirt3 alleles (Sirt3L2/L2) [7] with
CMV-Cre deleter mice that expressed Cre in the male
germline. Congenic C57BL6/J Sirt3-/- mice were gener-
ated through nine generations of backcrosses with
C57BL6/J mice. C57BL6/J LDL receptor knockout
(Sirt3?/?LDLR-/-) mice (Jackson Laboratories) were
crossbred with C57BL6/J Sirt3-/- mice to generate
C57BL6/J LDLR/Sirt3 double-knockout mice
(Sirt3-/-LDLR-/-). Eight-week-old male Sirt3?/?
LDLR-/-, Sirt3-/-LDLR-/-, and wild-type mice were fed
a 1.25 % (w/w) cholesterol diet (Research Diets) or normal
chow for 12 weeks and subsequently killed for fasted
(unless indicated otherwise) studies.
Assessment of atherosclerosis
En face analyses of thoraco-abdominal aortae were carried
out as previously described [24, 34, 42]. Briefly, thoraco-
abdominal aortae were excised and opened longitudinally.
Atherosclerotic plaques were visualized by fat staining
using Oil red O (ORO). In addition, plaque size and
composition were analyzed in serial longitudinal cryosec-
tions of aortic roots as described [34, 35]. Fibrous cap
thickness and necrotic core size were assessed by Sirius
Red staining. Necrotic cores were defined as areas free of
extracellular matrix between the luminal fibrous cap and
the collagen-rich outer intima and/or remaining media [28,
39]. Features of plaque vulnerability were characterized by
necrotic core diameter and fibrous cap thickness, each of
which was averaged from three different locations per
mouse (once underneath each valvular leaflet) in aortic root
cross sections.
Immunohistochemistry and immunofluorescence
Cryosections were blocked and stained using the following
antibodies: anti-CD68, anti-CD3, and anti-vascular adhe-
sion molecule-1 (VCAM-1; all Serotec). Collagen was
visualized using Sirius Red.
Electron microscopy
Mice were killed and perfused with 1 % formaldehyde and
2 % glutaraldehyde in phosphate buffer (PB; 0.1 M; pH
7.4). Aortae were explanted and aortic wall samples (rings
of 1 mm length) were extracted and postfixed by immer-
sion in the above-described fixative for 48 h followed by
three washes in PB and osmication in 1 % osmium
tetroxide for 1 h. After another three washes with PB,
samples were dehydrated in increasing alcohol gradients up
to 100 %, embedded in Epon/Araldite resin (Sigma-
Aldrich) overnight and polymerized at 60 C during 48 h.
Ultrathin sections, stained with 2 % aqueous uranyl acetate
and Reynolds lead citrate were imaged using a Phillips CM
100 transmission electron microscope (FEI, Eindhoven,
The Netherlands) equipped with a Gatan Orius CCD
camera and Digital Micrograph acquisition software (Ga-
tan). The cellular and subcellular structure of the inner
aortic wall, specifically the endothelial monolayer and
form as well as microarchitecture of endothelial mito-
chondria were assessed and compared in a qualitative
manner. One hundred mitochondria in at least three dif-
ferent animals per group were assessed.
Analysis of DNA damage
Aortic DNA was extracted by ethanol precipitation using
TRIzol reagent (Sigma-Aldrich). DNA lesion frequency,
halting DNA polymerase progression, was assessed using
long amplicon PCR as described [9, 17]. Amplification of
DNA polymerase b and b-globin were assessed as surro-
gate for genomic DNA lesion frequency. Amplification of a
117-bp and a 10-kb fragment of mitochondrial DNA was
assessed as surrogate for mitochondrial DNA damage,
which is specifically susceptible to oxidative damage. The
following primers were used: b-globin 5-TTG AGA CTG
TGA TTG GCA ATG CCT-30 (sense), 5-CCT TTA ATG
CCC ATC CCG GAC T-30 (anti-sense), DNA polymerase
b 5-TAT CTC TCT TCC TCT TCA CTT CTC CCC TGG-
30 (sense), 5-CGT GAT GCC GCC GTT GAG GGT CTC
CTG-30 (anti-sense), 10 kb mitochondrial fragment 5-GCC
AGC CTG ACC CAT AGC CAT AAT AT-30 (sense),
5-GAG AGA TTT TAT GGG TGT AAT GCG G-30 (anti-
sense), 117 bp mitochondrial fragment 5-CCC AGC TAC
TAC CAT CAT TCA AGT-30 (sense), 5-GAT GGT TTG
GGA GAT TGG TTG ATG T-30 (anti-sense).
Expression analyses
Aortic mRNA and protein were extracted using standard
protocols. mRNA expression was analyzed by quantitative
PCR using the following primers: NADP-dependent malic
enzyme 5-CAG GAA CCC CCA TCT CAA C-3 (sense),
5-ACATCCTGGCTGAGGAAGC-3 (anti-sense), nicotin-
amide nucleotide transhydrogenase 5-GAT CCA GAT
TTC CGA CTT GC-3 (sense), 5-ACT CTA CGA TGT
ACT CGG CCA-3 (anti-sense), glucose-6-phosphate
dehydrogenase 5-GTT GTA CCA GGG TGA TGC CT-3
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(sense), 5-GCC ACC AGA TGG TAG GAT AGA-3 (anti-
sense), 6-phosphogluconate dehydrogenase 5-GGGTC
ATCCTGCTTGTGAAG-3 (sense), 5-CATCGATGAT
GATGTCACCC-3 (anti-sense), isocitrate dehydrogenase 2
(IDH2) 5-CAG CAC TGA CTG TCC CCA G-3 (sense),
5-CAC CGT CCA TCT CCA CTA CC-3 (anti-sense),
catalase (cat) 50-CCC GCG GTC ATG ATA TTA AGT-30
(sense), 50-GAT GAA GCA GTG GAA GGA GC-30 (anti-
sense). Western blot analyses were performed according to
standard protocols. The following specific antibodies were
used: anti-SOD2 (Santa Cruz), anti-cat (Sigma).
Blood analyses
Prior to harvesting mice were fasted overnight. Blood was
drawn and citrate plasma was separated from corpuscular
elements by centrifugation at 4 C immediately and stored
at -80 C until analysis. Levels of interleukin 1b (IL-1b),
IL-6, monocyte chemotactic protein-1 (MCP-1), and tumor
necrosis factor alpha (TNFa) were determined using Bio-
Plex multiplex array systems (Bio-Rad Laboratories).
Plasma lipoprotein fraction distribution was measured
using a Roche-diagnostics Enzymatic kit for the Hitachi
902 robot according to the manufacturer’s instruction.
Plasma malondialdehyde (MDA) levels were determined
using the colorimetric AL detect lipid peroxidation assay
(Enzo Life Sciences) according to the manufacturer’s
instructions. Plasma glutathione reductase activity was
quantified based on the rate of NADPH oxidation using the
Glutathione Reductase Assay kit (Cayman Chemical)
according the manufacturer’s instructions. Isocitrate dehy-
drogenase 2 activity was assessed based on substrate turnover
using the Isocitrate Dehydrogenase Activity Colorimetric
Assay kit (Biovision) according to the manufacturer’s
instructions. The NADP/NADPH ratio was measured using
the NADP/NADPH Quantification kit (Biovision).
Glucose tolerance
For glucose tolerance tests a 200 mg/mL glucose solution
was prepared and injected into the intraperitoneal cavity at
2 g/kg body weight. At regular time intervals for up to 3 h
following administration, blood samples were taken and
glucose was measured.
Indirect calorimetry
A 12-chamber Oxymax system (Columbus Instruments)
with control of food access was used to measure oxygen
consumption, carbon dioxide production, food and water
intake, as well as locomotor activity in individually caged
mice at 23 C.
Mice were weighed and placed into individual metabolic
cages before measurements were started. Measurements
were performed for 3 days in the ad lib fed state (including
2 days of acclimatization); body weight was recorded
again at the end of day 3 to rule out a loss of weight during
‘‘basal’’ conditions. Food access was then halted for 15 h
(Fasting, from day 3, 5 pm through day 4, 8 am) and
restored thereafter (Refeeding). Body weight was recorded
again at the end of the experiment. Free access to water
was warranted during the whole experiment. Locomotor
activity (longitudinal ambulatory, ‘‘Xamb’’) was assessed
by infrared beam interruption.
The non-protein respiratory exchange ratio, a measure-
ment of metabolic substrate preference, was calculated as
the molar ratio of Vco2 to VO2. Heat (kcal/h) = VO2
(3.815 ? 1.232 RQ).
Individual averaged values of metabolic data (Heat, VO2
or respiratory quotient) for each light cycle were derived
for each mouse. Group averages are presented for each
genotype and light cycle.
Metabolic adaptation to Fasting was determined by
subtracting the individual averages of night 3 (fed) from
those of night 4 (fasted) for either heat, VO2 or the
Respiratory Quotient. Metabolic rebound upon refeeding
was assessed by subtracting the individual averages of
night 5 (refed) from those of night 4 (fasted). Metabolic
changes upon fasting and refeeding were also calculated as
percent change.
Mitochondrial acetylation, western blotting
Mitochondria were isolated from livers and gastrocnemius
muscle of mice by differential centrifugation using a
Mitochondrial Isolation kit (Abcam) according to the
manufacturer’s instructions. Thereafter, mitochondrial
protein was isolated, separated by electrophoresis and
blotted using standard protocols. Membranes were probed
using antibodies specific for ATPB (ATP-synthase subunit
b, Abcam), acetylated lysine (AcK, Cell Signaling), and
Sirt3. Antibodies recognizing murine Sirt3 were raised
against the C-terminal 15-amino-acid peptide (C)DL MQR
ERG KLD GQD R. The peptide was conjugated to the
carrier protein KLH by the added C residue and injected
into rabbits (Eurogentec). Antisera were purified using
immunoaffinity chromatography.
Statistical analysis
Metric variables were assessed for distribution using Kol-
mogorov–Smirnov tests. Different groups were compared
using unpaired Student’s t, Mann–Whitney U, Kruskal–
Wallis tests or two-way repeated measurements ANOVA
Page 4 of 15 Basic Res Cardiol (2014) 109:399
123
ORO
en face
0
1
2
3
4
5
ORO
cross section
0
10
20
30
40
50
C
D
A
B
O
RO
   
ar
ea
 [%
 to
tal
]
+
O
RO
  a
re
a 
[%
 to
tal
]
+
O
il R
ed
 O
O
il R
ed
 O
CD
68
CD
3
VC
AM
-1
E
3x 3x
p=0.940
Plaque macrophages
cross section
0
10
20
30
40
CD
68
   
ar
ea
 [%
 ro
ot]
+
Plaque T cells
cross section
0
50
100
150
200
CD
3 
  c
el
ls 
[no
. p
er 
pla
qu
e a
rea
]
+
0
10
20
30
40
VC
AM
-1
  a
re
a 
[%
 ro
ot]
+
p=0.834
p=0.806
p=0.783
p=0.444
Plaque VCAM-1
cross section
Sir
t3 
  L
DL
R
-
/-
-
/-
Sir
t3 
   L
DL
R
+/+
-
/-
Sir
t3 
  L
DL
R
-
/-
-
/-
Sir
t3 
   L
DL
R
+/+
-
/-
Sir
t3 
  L
DL
R
-
/-
-
/-
Sir
t3 
   L
DL
R
+/+
-
/-
Sir
t3 
  L
DL
R
-
/-
-
/-
Sir
t3 
   L
DL
R
+/+
-
/-
Sir
t3 
  L
DL
R
-
/-
-
/-
Sir
t3 
   L
DL
R
+/+
-
/-
Sirt3   LDLR-/--/-
Sirt3    LDLR+/+ -/-
Sirt3   LDLR-/- -/- Sirt3    LDLR+/+ -/-
Sirt3   LDLR-/- -/- Sirt3    LDLR+/+ -/-
Sirt3   LDLR-/- -/- Sirt3    LDLR+/+ -/-
Sirt3   LDLR-/- -/- Sirt3    LDLR+/+ -/-
Fig. 1 Loss of Sirt3 does not
affect atherosclerosis in LDLR
knockout mice after a high-
cholesterol diet. 8-week old
male Sirt3-/-LDLR-/- and
Sirt3?/?LDLR-/- mice were fed
a high-cholesterol diet (1.25 %
w/w) for 12 weeks before aortae
were excised. a Plaque burden
of thoraco-abdominal aortae en
face, stained with Oil Red O
(ORO), n = 10 per group. b–e
Cryosections of aortic roots,
n = 6 per group, stained with
Oil red O (ORO) (b), or
immunohistochemically for
CD68 (C), CD3 (d), or vascular
cell adhesion molecule-1
(VCAM-1) (e). Images are
representative micrographs, box
plots display interquartile
ranges, whiskers indicate
minima and maxima, scale bars
are 1 mm (a) and 500 lm (b–e)
Basic Res Cardiol (2014) 109:399 Page 5 of 15
123
with Bonferroni post hoc comparisons where appropriate.
Data are displayed as interquartile ranges ± minimal/
maximal values, unless indicated otherwise. Null-hypoth-
eses were rejected at p \ 0.05, p values are two-sided.
Analyses were done using Graphpad Prism version 5.0d
2010.
Results
Sirt3 deletion does not affect atherosclerosis
in LDLR-/- mice
After 12 weeks of high-cholesterol diet, the atherosclerotic
burden of Sirt3-/-LDLR-/- and Sirt3?/?LDLR-/- mice
was assessed en face in thoraco-abdominal aortae and cross
sections of aortic roots. Lesion distribution and depth, as
determined by ORO stainings, did not differ between the
two genotypes (Fig. 1a, b).
The cellular composition of atheromata was further
assessed in adjacent cross sections of the aortic root. No
differences in the immunohistochemical signals for CD68
and CD3 were observed, indicating that neither macro-
phage nor T cell infiltration were affected by deletion of
Sirt3 in this mouse model of atherosclerosis (Fig. 1c, d). To
address the degree of endothelial activation, VCAM-1
expression was investigated, again without uncovering a
difference between the two groups (Fig. 1e). Comple-
mentary analyses of plasma cytokine levels addressing a
potential systemic inflammatory phenotype revealed no
difference in IL1b, IL6, MPC-1, and TNFa between the
groups (Table 1A). Similarly, plasma total cholesterol,
HDL-cholesterol, LDL-cholesterol and triglyceride levels
did not differ significantly between the two groups
(Table 1B).
Loss of Sirt3 does not alter key features of plaque
vulnerability
In order to evaluate potential effects on features of plaque
vulnerability, we compared fibrous cap thickness and
necrotic core diameter in cross sections of the aortic roots
stained for collagen. Both fibrous cap thickness and
necrotic core diameter did not differ between
Sirt3-/-LDLR-/- and Sirt3?/?LDLR-/- mice (Fig. 2a, b).
With Sirt3 orchestrating mitochondrial metabolism, we
also addressed endothelial mitochondrial microarchitecture
in the aortic wall using electron microscopy. A qualitative
comparison of mitochondrial number and microarchitec-
ture revealed no Sirt3-dependent difference (Fig. 3a–f).
Sirt3 deficiency is associated with increased levels
of systemic but not aortic oxidative stress
To assess putative effects of Sirt3 on systemic oxidative
stress in this mouse model, plasma malondialdehyde (MDA)
levels were compared. Interestingly, MDA levels in
Sirt3-/-LDLR-/- mice were elevated compared with con-
trols (Fig. 4a). Yet, a comparison of oxidative damage to the
target tissue, the aortic wall, showed no Sirt3-dependent
difference. Both aortic genomic and mitochondrial DNA
lesion frequencies, as surrogate for oxidative DNA damage,
did not differ between Sirt3-/-LDLR-/- mice and LDLR-/-
controls (Fig. 4b, c and Fig S1). Accordingly, aortic
expression of the antioxidant enzymes superoxide dismutase
2 (SOD2) and catalase (cat) were unaffected by the lack of
Sirt3 (Fig. 4d–f). Moreover, aortic expression levels of the
key NADPH-producing or -regenerating enzymes, including
isocitrate dehydrogenase 2 (IDH2) and malic enzyme, were
unaltered between the two groups (Fig S2). Interestingly,
also systemic activity levels of IDH2 and glutathione
reductase (GR) as well as plasma ratios of NADP/NADPH
did not differ between the two groups (Fig. 4g–i). These
findings indicate that depressed glutathione regeneration was
not responsible for the observed increase in systemic oxi-
dative stress in Sirt3-/- mice. In absence of an antioxidative
effect within the vessel wall, and given the lack of an effect
of Sirt3 deletion on atherosclerosis, the increase in systemic
oxidative stress appears unlikely to affect vascular inflam-
mation and atherosclerotic burden in the context of
advanced atherosclerosis.
In order to confirm a difference in Sirt3 activity in the
current model (LDLR-/- mice on a high-cholesterol diet),
we analyzed global mitochondrial protein acetylation in
isolated hepatic and skeletal muscle mitochondria. Sirt3
deletion was associated with a marked mitochondrial pro-
tein hyperacetylation, suggesting a relevant difference in
Sirt3 activity (Fig. 5, Fig S3C). To further exclude a diet- or
LDLR-dependent blunting of Sirt3 activity, hepatic
Table 1 Deletion of Sirt3 does not affect plasma cytokine or lipid
levels
Sirt3?/?
LDLR-/-
Sirt3-/-
LDLR-/-
p value
A) Plasma cytokine levels
IL-1b (pg/ml) 99.9 ± 17.5 128.6 ± 20.6 0.317
IL-6 (pg/ml) 2.6 ± 0.3 3.6 ± 0.3 0.073
MCP-1 (pg/ml) 34.4 ± 2.1 48.9 ± 3.8 0.052
TNFa (pg/ml) 1.2 ± 0.0 1.2 ± 0.0 0.502
B) Plasma lipid levels
Total cholesterol (mmol/l) 30.6 ± 5.0 26.2 ± 1.6 0.421
LDL-cholesterol (mmol/l) 20.9 ± 1.8 25.4 ± 4.6 0.385
HDL-cholesterol (mmol/l) 4.7 ± 0.4 5.1 ± 0.2 0.331
Triglycerides (mmol/l) 2.60 ± 0.33 2.11 ± 0.19 0.202
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mitochondrial acetylation was assessed in Sirt3-/-LDLR?/?
and Sirt3?/?LDLR?/? mice fed a high-cholesterol diet or
normal chow. Mitochondrial hyperacetylation in absence of
Sirt3 compared with Sirt3?/? controls was similar in all
settings (Fig S3).
Body weight and plasma glucose levels are increased
in absence of Sirt3
Sirt3-/-LDLR-/- mice were consistently heavier than
controls (Fig. 6a). Moreover, both fed and fasted blood
glucose levels were increased in absence of Sirt3 (Fig. 6b).
To address whether this difference was due to a restricted
capacity to metabolize glucose, we compared glucose
clearance after an intraperitoneal glucose challenge. Inter-
estingly, loss of Sirt3 did not affect glucose clearance
(Fig. 6c). Moreover, plasma free fatty acid levels did not
differ between Sirt3-/-LDLR-/- and control mice
(Fig. 6d).
In order to rule out that the difference in body weight
was related to an organ-specific phenotype or organo-
megaly, liver, spleen and epididymal white adipose tissue
weights (WAT) were assessed. No difference between the
two genotypes was observed (Fig S4).
Loss of Sirt3 impairs metabolic adaptation to rapid
changes in energy supply
To further investigate the metabolic phenotype of
Sirt3-/-LDLR-/- mice and Sirt3?/?LDLR-/- controls, we
compared their metabolic rates, oxygen consumption along
with locomotion and food intake continuously during a
period of 5 light cycles including a 15-h fasting period
beginning at the end of day 3 (D3).
During the ad libitum (ad lib) period [night 1 (N1) to D3]
Sirt3-/-LDLR-/- mice showed a higher metabolic rate
compared with controls (Fig. 7a, b left panel). The fasting-
induced heat-drop was more pronounced in Sirt3-/-LDLR-/-
mice compared with controls (27 vs. 20 %), blunting the pre-
existing difference to controls (Fig. 7a, b). Importantly, oxy-
gen consumption (VO2), taking individual body weight into
account, did not differ between the two genotypes during the
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Fig. 2 Deletion of Sirt3 does
not affect features of plaque
stability. Sirt3-/-LDLR-/- and
Sirt3?/?LDLR-/- mice were
treated as described and aortae
excised. a Cryosections of aortic
roots, stained for collagen with
Sirius red, n = 6 per group.
b Quantification of fibrous cap
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representative micrographs, box
plots display interquartile
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ad lib period (Fig. 7c, left panel). However, the fasting-
induced VO2-drop was also more pronounced in
Sirt3-/-LDLR-/- mice compared with Sirt3?/?LDLR-/-
controls (24 vs. 17 %; Fig. 7c, right panels). Thus, depletion
of Sirt3 was associated with an exaggerated fasting-induced
hypo-metabolism compared with controls. This exaggerated
hypo-metabolism upon fasting in absence of Sirt3 could not
be explained by an inability to rely on lipid utilization during
fasting since respiratory exchange ratios (RER) dropped to
similarly low values in Sirt3-/-LDLR-/- mice and Sirt3?/?
LDLR-/- controls (Fig S5A). Whereas cumulative food intake
differed between the two groups, there was no difference
when food intake was normalized to body weight (Fig S5B).
The experiment itself had no effect on the body weight of the
animals (Fig S5C).
During refeeding the metabolic rebound from the fasted
state was nearly twice as pronounced in Sirt3-/-LDLR-/-
mice compared with controls, with heat rebound of 32 vs.
19 % in the control group and VO2 rebound of 26 vs. 14 %
in controls (Fig. 7a–c). Refeeding behavior in terms of
body weight-adjusted food intake and locomotion did not
differ between the two groups (Fig. 7d, e, Fig S5B), indi-
cating a metabolic rather than a behavioral phenotype.
Discussion
Principle findings
We demonstrate for the first time that constitutive Sirt3
deletion, despite increased systemic levels of oxidative
stress, neither affects the atherosclerotic burden nor fea-
tures of plaque stability in LDLR-/- mice. On the other
hand, Sirt3 deficiency led to a slight increase in fasting
glucose levels, whereas glucose tolerance and plasma lipid
levels remained unaltered. Yet, Sirt3 deletion was associ-
ated with an accelerated weight gain and an impaired
capacity to cope with rapid changes in nutrient supply,
showing an exaggerated fasting-induced hypo-metabolism.
Similar respiratory exchange ratios rule out a Sirt3-
dependent inability to rely on lipid metabolism during
fasting in the applied mouse model.
Added value
To date no report on the role of Sirt3 in vascular diseases
exists. With Sirt3 regulating mitochondrial oxidative metab-
olism and governing several ROS detoxifying systems [1, 14,
36, 38, 43], we postulated an atheroprotective role of Sirt3.
Unexpectedly, Sirt3 deletion had neither relevant effects on
the atherosclerotic burden nor on plaque stability. It can be
speculated whether the lack of an atherosclerotic phenotype
may be explained by model-associated specificities: the
NAD?-dependence of sirtuins, confining their maximal
activity to times of energy deprivation, may interfere with the
atherogenic high-cholesterol diet applied in this study; i.e.,
Sirt3 activity in the control group may have been decreased
by this high-caloric diet. However, the marked mitochondrial
protein hyperacetylation in Sirt3-/-LDLR-/- compared with
Sirt3?/?LDLR-/- mice implies a relevant difference in Sirt3
activity between the groups investigated. Although currently
only indirect evidence suggesting a role for Sirt3 in cellular
lipid uptake exists [19, 32], an intact cholesterol uptake and
metabolism system may be required for certain Sirt3-medi-
ated effects. Thus, the absence of the LDL receptor may
interfere with distinct downstream effects.
In line with previous reports that assign Sirt3 a protec-
tive role in diverse settings of oxidative damage [4, 18, 22,
33, 36], we observed increased systemic MDA levels in
Sirt3-deficient hyperlipidemic mice compared with con-
trols. In contrast to Someya et al. [32], who report on a
Sirt3-dependent glutathione-mediated oxidative detoxifi-
cation, glutathione reductase activity levels did not differ in
the current study, suggesting other antioxidant mechanisms
such as MnSOD and catalase [4, 29, 36] to be responsible
for the Sirt3-mediated antioxidant protection.
Hirschey et al. [15] recently reported that Sirt3 deletion
accelerated the development of the metabolic syndrome in
mice when fed a high-fat diet. Sirt3-/- mice developed
bFig. 3 Sirt3 deficiency does not affect endothelial mitochondrial
architecture in the aortic wall. Sirt3-/-LDLR-/- and Sirt3?/?
LDLR-/- mice were treated as described and aortae excised and
cross sections of the thoracic descending aorta were imaged using
electron microscopy. a, b Overview of the inner vascular wall (from
left to right): endothelial monolayer with endothelial nuclei (Ncl)
protruding towards the lumen, elastica interna, vascular smooth
muscle cell layer. c, d Magnification of an endothelial cell, allowing
the differentiation of its subcellular components, including mitochon-
dria (M). e, f Magnification of a single endothelial mitochondrion,
showing mitochondrial microarchitecture. Images are representative
micrographs of n = 5 per group and 100 mitochondria per aortic
phenotype, and serve for qualitative comparisons only. M mitochon-
drion, Ncl nucleus, ER endoplasmic reticulum
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Fig. 4 Loss of Sirt3 increases systemic oxidative stress without
affecting vascular oxidative DNA damage. Sirt3-/-LDLR-/- and
Sirt3?/?LDLR-/- mice were treated as described, blood was drawn
and aortas were explanted. a Malondialdehyde (MDA) levels as
surrogate for systemic oxidative stress, n = 8 per group. b Aortic
DNA was isolated and relative oxidative damage of genomic (b) and
mitochondrial DNA c was assessed using quantitative PCR. b Lesion
frequency and the resulting copy number of DNA polymerase b as
surrogate for genomic DNA damage, n = 10 per group. c Lesion
frequency and the resulting copy number of a 1 kb mitochondrial
DNA fragment as surrogate for mitochondrial DNA damage, n = 10
per group. d–f Expression of catalase (cat) and superoxide dismutase
2 (SOD2) were assessed using quantitative PCR, n = 9 per group (d,
e) and by western blot, n = 5 per group (f). g Plasma isocitrate
dehydrogenase 2 (IDH2) activity, n = 9 per group. h Plasma
glutathione reductase (GR) activity, n = 6 per group. i Plasma
NADP/NADPH ratio, n = 5 per group. Box plots display interquartile
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accelerated obesity, insulin resistance, and hyperlipidemia.
In parallel, loss of Sirt3 was associated with accelerated
weight gain and elevated plasma glucose in LDLR-/- mice
in the current study; however, without affecting serum lipid
levels or glucose tolerance, thus not fulfilling the criteria for
a full-grown metabolic syndrome [2]. Detailed assessment
of this metabolic phenotype showed an impaired capacity of
Sirt3-deficient mice to cope with rapid changes in nutrient
supply. Although driving not only glucose and amino acid
catabolism, but also fatty acid oxidation in times of energy
deprivation [14], similar respiratory exchange ratios both
during fed ad libitum and fasting periods rule out an
impaired fatty acid utilization in absence of Sirt3. Interest-
ingly, neither muscle- nor liver-specific loss of Sirt3 did
manifest any metabolic phenotype under either chow or
high-fat diet [7], indicating that either another organ or the
interplay between different organs are necessary for Sirt3 to
exert its metabolic functions in its entirety.
Potential limitations
This study has to be interpreted in light of the following lim-
itations: experiments have been carried out in an LDLR-/-
model using a high-cholesterol diet. Therefore, a potential
interplay between Sirt3 and the LDL receptor in wild-type
mice under similar conditions cannot be excluded. However,
to date no evidence for an LDLR-mediated role of Sirt3 exists.
Moreover, a putative effect of Sirt3 on early atherosclerosis or
vascular function was not assessed. Given the increased MDA
levels in Sirt3-deficient mice Sirt3 may affect endothelial
relaxation, thereby affecting the initial disposition for ath-
erogenesis. In addition, a diet-induced blunting of Sirt3
activity cannot be ruled out completely. However, a persistent
mitochondrial hyperacetylation in Sirt3-deficient mice, irre-
spective of the diet supplied or LDLR expression strongly
suggests no relevant diet- or LDLR-dependent blunting of
Sirt3 activity. Moreover, the electron microscopy-based
analyses of the inner aortic wall and endothelial subcellular
structures are qualitative in nature; no quantitative statements
can be made. Finally, the exact mechanisms underlying the
constrained ability of Sirt3-deficient mice to cope with rapid
changes in nutrient supply and the causes of the accelerated
weight gain remain to be determined.
Implications
The current study provides a first step in unraveling the role
of Sirt3, a key enzyme in metabolic regulation and ROS
homeostasis, in vascular disease. Surprisingly, no effects
on advanced atherosclerotic lesions were observed, even
though levels of systemic oxidative stress were increased in
absence of Sirt3. A striking acceleration in weight gain and
an impaired capacity to react to rapid changes in nutrient
supply underline the importance of Sirt3 in energy
homeostasis. The latter findings assign Sirt3 a potential role
in the development of cardiovascular risk factors, post-
poning the onset of distinct metabolic risk factors.
Further studies will be needed to determine the role of
Sirt3 on vascular function; a reassessment of putative
effects on atherosclerosis using gain-of-function studies,
in the absence of a high-caloric diet, and an extended
analysis of the metabolic phenotype of Sirt3 on a wild-
type background and chow diet will shed further light on
the putative protective roles of Sirt3 in vascular health
and disease.
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Fig. 6 Deletion of Sirt3
accelerates weight gain and
increases plasma glucose levels.
Sirt3-/-LDLR-/- and Sirt3?/?
LDLR-/- mice were fed a high-
cholesterol diet (1.25 % w/w)
for 12 weeks. a Weight gain
during treatment (left panel) and
its quantification comparing
areas under the curve (AUC,
right panel). b Plasma glucose
levels, fed (left panel) and
fasted (right panel). c Plasma
glucose levels upon
intraperitoneal glucose
challenge (2 g/kg body weight)
(left panel), quantification
comparing areas under the curve
(AUC, right panel). d Plasma
free fatty acid (FFA) content,
fed (left panel) and fasted (right
panel). Data are
means ± SEMs with
superimposition of individual
data points in all panels except
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Fig. 7 Loss of Sirt3 impairs metabolic adaptation to rapid changes in
energy supply. After a 12-week high-cholesterol diet (1.25 % w/w)
different metabolic parameters were assessed in individually caged
Sirt3-/-LDLR-/- and Sirt3?/?LDLR-/- mice during five light cycles.
a, b Metabolic rate (heat production): circadian profile during an
ad libitum fed state (night 1 to day 3), during a 15-h overnight fasting
period (5 pm, day 3 through 8 am, day 4) and during subsequent
refeeding (day 4, night 5), N night, D day. b Average metabolic rates
per day/night (left panel); metabolic drop during fasting (‘‘delta night
3 vs. night 4’’, center panel), and metabolic rebound upon refeeding
(‘‘delta night 4 vs. night 5’’, right panel). c Average oxygen
consumption (VO2) per day/night (left panel); VO2 drop during fasting
(‘‘delta night 3 vs. night 4’’, center panel), and VO2 rebound upon
refeeding (‘‘delta night 4 vs. night 5’’, right panel). d Average
locomotor activity per day/night. e Average food intake per day/night.
Data are means ± SEM, with superimposition of individual data
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